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464ms). U wave was present in 16% of patients with ED and 4% in controls
(p=0.006).
BMI and heart rate were negatively correlated with QT in univariate ana-
lysis. After adjustment for BMI and heart rate, QT was significantly lower in
patients with ED in leads II, V2 and V5 (p<0.05). 
Corrected QT tended to be increased in ED patients receiving drugs known
to increase QT (p = 0.1). QT was negatively correlated to plasma magnesium
level (p = 0.01), to calcemia (p = 0.06) and to plasma albumin (p = 0.004).
QT was not associated to plasma potassium level. QT did not differ between
the different types of ED.
No patient did present with major event before inclusion or during follow-
up.
Conclusion: QT durations were found normal in patients with ED and
were even shorter than in controls when corrected or adjusted for heart rate.
QT was only related to BMI, calcium and magnesium plasma levels.
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Introduction and objectives: The risk of stroke in atrial fibrillation is
heterogeneous and depends upon underlying clinical conditions included in
current risk stratification schemes. Recently, the CHA2DS2-VASc score has
been included in guidelines to be more inclusive of common stroke risk fac-
tors seen in everyday clinical practice, and useful in defining ‘‘truly low risk”
subjects. We aimed to assess the usefulness of CHA2DS2-VASc score to give
us an additional prognostic perspective for adverse events and mortality
among ‘‘real world” anticoagulated patients with atrial fibrillation who are
often elderly with many comorbidities.
Methods: Consecutive outpatients with permanent/paroxysmal non val-
vular atrial fibrillation with CHA2DS2-VASc > ou = a 2 and stabilized oral
anticoagulation (international normalized ratio 2.0-3.0) for at least the pre-
ceding 6 months were recruited. Patients with CHA2DS2-VASc > ou = a 2
were selected. Adverse cardiovascular events including stroke, acute coronary
syndrome, or heart failure; major bleeds; and mortality were recorded during
more than 2 -year-follow-up.
Results: Of 293 patients (93.5%) assessed, 167 were males, median age 76
(71-81) years. After a followup of 567 (432-665) days, 11.7% patients had
adverse cardiovascular events, 8.6%patients had major bleeds, 10.8% patients
died, and 24.6% major adverse events (composite endpoint).Increasing
CHA2DS2-VASc score by 1 point had a significant impact on the occurrence
of cardiovascular events (hazard ratio=1.27; 95% confidence interval, 1.13-
1.44; P<.001), mortality (hazard ratio=1.36; 95% confidence interval, 1.19-
1.54, P<.001); and major adverse events (hazard ratio=1.23; 95% confidence
interval, 1.13-1.34; P<.001). CHA2DS2-VASc score was not associated with
major bleeding episodes.
Conclusions: Among high risk atrial fibrillation patients on oral anticoa-
gulation, CHA2DS2-VASc successfully predicts cardiovascular events and
mortality, but not major bleeds.
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Background: It is well established that tonic-clonic seizure-like activity
can be part of a syncope yet many patients with these clinical features are mis-
diagnosed with seizures and often referred to epilepsy centers. Head-up tilt
test (HUT) is the gold standard for diagnosing vasovagal syncope, but it can
fail to provide clinical details that help distinguish convulsive syncope from
epileptic seizures. We aimed to evaluate the diagnostic yield of a combined
HUT and video-EEG monitoring strategy in patients with atypical episodes of
unexplained loss of consciousness (LOC).
Methods and results: A total of 87 patients (mean age 32±15 years, 71%
women) who underwent HUT with concomitant video-EEG between March
2007 and August 2013 were retrospectively analyzed. Events were classified
as vasovagal syncope, epilepsy or psychogenic. Median number of episodes of
LOC was 6 [range 1 – 30]. 45% of patients had prolonged LOC (>1 min),
75% had myoclonic jerks and 52% abnormal standard EEG. Antiepileptic
drugs (AEDs) were prescribed in 38 patients (43%). The majority of patients
(78/87) had undergone prior neurological and cardiac evaluation with routine
EEG, neuroimaging and/or Holter ECG, and HUT (n=30). HUT combined
with video-EEG was diagnostic in 67/87 (77%) of patients. Vasovagal syn-
cope was seen in 62/87 (71%), 31 of which had associated myoclonic jerks,
especially dose with severe bradycardia ≤40 bpm (n=26) or asystole (n=5).
Five patients (6%) experienced psychogenic non-epileptic events. Epilepsy
was diagnosed in only 8 patients (9%), and LOC remained unexplained in 12
(14%). AEDs were discontinued in non-epileptic patients as a result of the
testing.
Conclusions: Patients with convulsive syncope are often misdiagnosed and
treated with AEDs. Combined HUT and video-EEG monitoring is a useful
diagnostic test in patients with atypical episodes of unexplained LOC and can
avoid expensive non-diagnostic evaluations as well as ongoing treatment with
unnecessary AEDs. 
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Background: Implantable cardioverter-defibrillator (ICD) the best treat-
ment for secondary prevention in Brugada syndrome (BrS). However, asymp-
tomatic patients are still being implanted, regardless the high rate of device
complications. We compared the occurrence of complications in patients
implanted an ICD in several French centers. 
Method and results: Consecutive BrS Patients implanted an ICD for
primary or secondary prevention were studied. Per- and post-implantation
complications, and ICD programming controls were recorded. Patients or
relatives were also contacted by telephone to check last news (alive or
died). We studied 51 patients (mean age of 46.7±10.5 years, 10% of
female). Spontaneous type 1 ECG pattern was found in 40 (78%) of
patients and atrial fibrillation in 6 (12%). Prior to ICD implantation, No
symptom, Syncope, and aborted cardiac arrest were found in 19 (37%), 24
(47%), and 8 (16%) patients respectively. During a median follow-up
period of 76±41.7 months (at 1 to 192), appropriate ICD shocks occurred
in 11 (21.5%) patients of whom 90% had spontaneous coved type ECG,
40% had previous syncope and 60% already have experienced aborted
SCD. Seven (13.7%) patients had inappropriate shocks (IS), of whom 5
(71.4%) in asymptomatic, 28.6% in syncope group, and none in resusci-
tated group. Other Complications were reported in 10 (19.6%) patients.
Lead fracture, Lead dislodgement, pneumothorax, pocket infection, myo-
cardial perforation, and re-operation for any reason occurred in 4 (7.8%),
2 (3.9%), 1 (1.9%), 1 (1.9%), 1 (1.9%), and 9 (17.6%) respectively. The
incidence of IS is higher in asymptomatic vs symptomatic patients if we
consider the confidence interval of 90% (p=0.07) in this rare disease,
whereas other complications had similar rate occurrence. 
Conclusion: ICD was shown to be an effective therapy in symptomatic
patients, particularly in those with previous cardiac arrest. However, the high
rate of device complications, mainly inappropriate therapies recommends to
accurately assess the risk-benefit of cardioverter-defibrillator and avoid this
treatment in asymptomatic patients.
